Loading..
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in Brief
    • Vision
    • Mission
    • History
    • Organisation
    • Collaborations and Partnerships
  • Our Science
    • Resolving Inflammation
    • The Melanocortin System and Inflammation
    • SynAct’s Technology – Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The resomelagon (AP1189) Development Program
      • Rheumatoid Arthritis
      • Membranous Nephropathy
      • Virus Induced Respiratory Insufficiency
    • Peptide Agonists
      • TXP-11
  • Investors
    • Capital Markets Day 2024
    • Investment highlights
    • Word from the CEO
    • Financial Reports
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectus and rights issues
      • 2025
      • 2024
      • 2023
      • 2022
      • Older
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact

Calendar

2017
  • Upcoming events
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • All years
  • 27
    Jan
    January 27, 2017
    SynAct Pharma presenterar i Köpenhamn
    Add to calendar
  • 31
    Jan
    January 31, 2017
    SynAct Pharma presenterar på Aktiedagen i Lund
    Add to calendar
  • 09
    Feb
    February 9, 2017
    Bokslutskommuniké för 2016
    Add to calendar
  • 08
    Mar
    March 8, 2017
    SynAct Pharma presenterar på Life Science-dagen 2017
    Add to calendar
  • 10
    Mar
    March 10, 2017
    SynAct Pharma presenterar i Stockholm
    Add to calendar
  • 14
    Mar
    March 14, 2017
    SynAct Pharma presenterar på Aktiedagen i Jönköping
    Add to calendar
  • 11
    May
    May 11, 2017
    Årsstämma 2017
    Add to calendar
  • 11
    May
    May 11, 2017
    Delårsrapport Q1 2017
    Add to calendar
  • 31
    Aug
    August 31, 2017
    Halvårsrapport 2017
    Add to calendar
  • 03
    Nov
    November 3, 2017
    Delårsrapport Q3 2017
    Add to calendar
  • 06
    Nov
    November 6 - November 7, 2017
    BIO-Europe Berlin
    Add to calendar
  • 16
    Nov
    November 16, 2017
    Sedermeradagen Stockholm
    Add to calendar
  • Investors
    • Capital Markets Day 2024
    • Investment highlights
    • Word from the CEO
    • Financial Reports
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectus and rights issues
      • 2025
      • 2024
      • 2023
      • 2022
      • Older
Jeppe Øvlesen
Jeppe Øvlesen
Chief Executive Officer and Board Member
+45 28 44 75 67
[email protected]
Björn Westberg
Björn Westberg
Chief Financial Officer
[email protected]

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • LinkedIn

Subscribe